

Jerrold Ellner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/550348/publications.pdf>

Version: 2024-02-01

21
papers

1,930
citations

471061

17
h-index

713013

21
g-index

21
all docs

21
docs citations

21
times ranked

1426
citing authors

#	ARTICLE	IF	CITATIONS
1	Accelerated course of human immunodeficiency virus infection after tuberculosis.. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 129-135.	2.5	494
2	A Trial of Three Regimens to Prevent Tuberculosis in Ugandan Adults Infected with the Human Immunodeficiency Virus. New England Journal of Medicine, 1997, 337, 801-808.	13.9	381
3	CEPHALOTHIN PLUS AN AMINOGLYCOSIDE IS MORE NEPHROTOXIC THAN METHICILLIN PLUS AN AMINOGLYCOSIDE. Lancet, The, 1978, 312, 604-606.	6.3	147
4	Tuberculosis in Household Contacts of Infectious Cases in Kampala, Uganda. American Journal of Epidemiology, 2003, 158, 887-898.	1.6	147
5	Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. Aids, 2001, 15, 2137-2147.	1.0	130
6	Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet, The, 1994, 344, 1323-1328.	6.3	103
7	Pentoxifylline Therapy in Human Immunodeficiency Virus-Seropositive Persons with Tuberculosis: A Randomized, Controlled Trial. Journal of Infectious Diseases, 1996, 174, 727-733.	1.9	73
8	Cellular Immunity to Human Immunodeficiency Virus Type 1 (HIV-1) Clades: Relevance to HIV-1 Vaccine Trials in Uganda. Journal of Infectious Diseases, 2000, 182, 1350-1356.	1.9	67
9	Mycobacterium africanum Subtype II Is Associated with Two Distinct Genotypes and Is a Major Cause of Human Tuberculosis in Kampala, Uganda. Journal of Clinical Microbiology, 2002, 40, 3398-3405.	1.8	56
10	Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. The Makerere University-Case Western Reserve University Research Collaboration.. American Journal of Respiratory and Critical Care Medicine, 1996, 153, 1977-1981.	2.5	53
11	Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. Aids, 1997, 11, 455-460.	1.0	50
12	Predicting the Outcome of Therapy for Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 1076-1080.	2.5	42
13	Instability of Tuberculin and Candida Skin Test Reactivity in HIV-infected Ugandans. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1790-1796.	2.5	36
14	Immune activation, allergic drug toxicity and mortality in HIV-positive tuberculosis. Tubercle and Lung Disease, 1996, 77, 516-523.	2.1	34
15	Clinical Research and Development of Tuberculosis Diagnostics: Moving From Silos to Synergy. Journal of Infectious Diseases, 2012, 205, S159-S168.	1.9	30
16	Activation of Chemokines and CCR5 in Persons Infected with Human Immunodeficiency Virus Type 1 and Tuberculosis. Journal of Infectious Diseases, 2001, 183, 1801-1804.	1.9	29
17	To Biopsy or Not to Biopsy in suspected Herpes Simplex Encephalitis. Medical Decision Making, 1988, 8, 95-101.	1.2	19
18	A possible role for cold insoluble globulin in chemotactic factor mediated polymorphonuclear leukocyte adherence to plastic. Biochemical and Biophysical Research Communications, 1982, 106, 471-478.	1.0	17

#	ARTICLE	IF	CITATIONS
19	Comparison of rapid tests for detection of rifampicin-resistant Mycobacterium tuberculosis in Kampala, Uganda. BMC Infectious Diseases, 2009, 9, 139.	1.3	12
20	Comparison of the activity of fluoroquinolones against Mycobacterium avium in cell-free systems and a human monocyte in-vitro infection model. Journal of Antimicrobial Chemotherapy, 1996, 37, 491-500.	1.3	9
21	Comparison of IGRA and TST in the diagnosis of latent tuberculosis among women of reproductive age in SOUTH India. Indian Journal of Tuberculosis, 2022, , .	0.3	1